Trial Profile

A Phase 3, Randomised, Investigator-blind, Active-controlled, Parallel Group, Multicentre Trial Comparing the Efficacy and Safety of 4-weeks Treatment With LEO 90100 and Daivobet Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Sep 2024 According to a LEO Pharma Media Release, Zhang Jianzhong is lead investigator of this phase 3 Enstilar trial.
27 Sep 2024 According to a LEO Pharma Media Release, company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), Based on results from this trial.
07 May 2024 According to a LEO Pharma Media Release, following the results, company will proceed with preparations to submit Enstilar for approval with the Chinese authorities.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com